|
Clozapine
Davis publishers, 200 ralph myerson, user contributions: the following comments are not guaranteed to be that of a trained medical professional.
Participation in Treatment Planning, W0484-Direct Care by Physician, W0357-Crisis Intervention, W0354-Crisis Stabilization, W0480-Individual Family Therapy, W0482-Group Therapy, W0314-Individual Supportive Counseling, H5020-Supportive Group Counseling, W0466, W0468, W0490, W0492-Basic Living Skills, 90862-Pharmacologic Management, W0346-Clozaril Clozapine, W0356-Behavior Management Plan Development, W0355-Behavior Management Implementation, W0402-Psychological Interview and Report, W0410-Standardized Individual Intellectual Evaluation, W0420-Diagnostic Personality Evaluation, W0430-Standardized Individual Achievement Evaluation, W0440-Psychological Screening Instruments, W0450-Adaptive Behavior Scales. Note: Clinical Evaluations Assessments continue as a requirement after an individual begins receiving Assertive Community Treatment ACT ; and must be submitted at the required intervals in order to validate medical necessity for continuance of Rehabilitation Services. As Clinical Evaluation-W0352 is included in ACT services, no billing can occur outside of the ACT code-W0366 for this service. When an ACT consumer is hospitalized for a psychiatric condition billing for ACT will not occur, though the ACT team must maintain contact and be part of the hospital discharge efforts. W0360-Day Treatment is not a recommended service for Assertive Community Treatment. If Day Treatment is needed and provided to an ACT eligible individual it may not be billed separately. Also no Psychiatric CPT codes nor Personal Care Codes W0305 or W0306 ; may be billed for someone receiving in ACT. The following Rehabilitation Service is available to an individual based on medical necessity outside of the ACT set of services: W0376-Case Consultation. Consumer Medical Record and Documentation Standards: A. For each consumer, the ACT team shall maintain a treatment record that is confidential, complete, accurate, and contains up-to-date information relevant to the consumer's care and treatment. The individual consumer record must document and contain supporting documentation showing that the consumer meets eligibility criteria for the service. Authorization from the Bureau for Medical Services must be maintained in the consumer record. B. The record shall sufficiently document assessments, treatment plans, and the nature and extent of services provided, such that a person unfamiliar with the ACT team can identify the 61.
N euroreceptor a ffinity like clozapine, quetiapine binds to a range of receptors including dopamine d 1 and d 2 , serotonin 5-ht 2a and 5-ht 1a , histamine, and adrenergic a 1 and a 2 sites.
North America . 18, 947 Europe . 43, 250 Latin America . 14, 686 Animal Health . 379, 497, because clozapine withdrawal!
Correspondence: David W. Carley, Ph.D., University of Illinois at Chicago, Section of Respiratory and Critical Care Medicine, MC787, 840 South Wood Street, Chicago, IL 60612, Tel: 312-996-3827, Fax: 312-996-1225, Email: DWCarley uic.
3.01 et seq. MISLEADING DOMAIN NAME AND SITE A. Initial Interest Confusion B. Actual Confusion 4.01 et seq. TRADEMARK, COMMON LAW AND REGISTERED A. General Overview B. Common Law Rights i ; Establishing Right ii ; Failing to Establish Right C. Registration Rights i ; Prima Facie Validity ii ; Disclaimers, USPTO and mebeverine.
Angioedema and anaphylaxis the onset of angioedema, which is simply swelling, often accompanying anaphylaxis, is a major medical concern at all times during a pregnancy.
Risperidone, olanzapine, and quetiapine are the most commonly used atypicals in this setting; clozapine is less often prescribed because of its blood monitoring requirement and combivir.
A single kaletra tablet contains 200mg of lopinavir and 50mg of ritonavir.
GENERAL HOSPITAL GENERAL HOSPITAL GENERAL HOSPITAL UTOPIAN T.O.CHEMICAL NIDA PHARMA OTSUKA OTSUKA OTSUKA ROCHE DIAGNOSTICS JOHNSON&JOHNSON POSE HEALTH CARE GPO GENERAL DRUG HOUSE JOHNSON&JOHNSON NEOPLAST PHARMALAND PHARMALAND POSE HEALTH CARE UMEDA CHUGAI PHARM CO GPO VIDHYASOM VIDHYASOM GPO and lamivudine.
INDICATIONS Insulin shock w unconscious patient when D50 is not available or an IV line can't be established. Cardiac arrest patients taking blocking agents. Esophageal food obstruction.
Of questions A numberclozapine do themay be asked, including: How atypicals compare with and the conventional neuroleptics in terms of clinical efficacy? Are the side effects of all atypicals less than those of the conventional neuroleptics? How effective are conventional and atypical drugs as regards overall system response? Atypicals versus clozapine According to a Cochrane review, 1 which used a global clinical index, new atypicals are broadly similar to clozapine, but this is based on only a small number of studies of short duration. Cloza0ine gives rise to more symptoms of fatigue, hypersalivation and orthostatic dizziness. The newer atypicals show more extrapyramidal side effects with the exception of olanzapine. Weight gain remains a problem with all the conventional antipsychotic drugs and with the atypicals, including olanzapine and clozapine. Some patients are more affected by this but the prediction of who will show weight gain remains uncertain. The Cochrane report emphasises that the impact on quality of life, service use and hospital admission and economics have not been reviewed.The overall conclusion is that equal effectiveness and tolerability in comparison with clozapine is not yet demonstrated and zidovudine.
Drug metab dispos 30 : 1280- 2002.
Risperidone and ziprasidone may have a lower risk for weight gain than do clozapine and olanzapine but studies to date have been limited and compazine.
Consensus Opinion. There is sufficient evidence to conclude that SGAs are less likely to cause TD than FGAs are. Level 1 ; Background. There is evidence that newer antipsychotics are associated with a reduced risk of causing TD. The best evidence is for clozapine Kane et al. 1993 ; . A study of olanzapine Tollefson et al. 1997 ; and a study of risperidone in elderly patients Jeste et al. 1999 ; both indicate that the SGA was associated with a reduced risk of TD. Although these studies are not conclusive, they suggest that the risk of TD will be reduced when patients are changed to a newer drug. Other preliminary reports with risperidone and quetiapine support the lower incidence on newer drugs. These findings also suggest--although they do not prove--that patients who have TD may demonstrate greater improvement in their movements if they are managed with an SGA. Because the design of studies that would provide such proof raises ethical concerns, it is unlikely that evidence will emerge during the next several years proving or disproving that SGAs are associated with a reduced risk of TD. However, the evidence that SGAs are less likely to cause TD is substantial and should, therefore, guide antipsychotic drug selection.
25 4 ; : 461- bondolfi et al, 1998 ; risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study and prochlorperazine.
Condition sufficiently severe or unstable to be considered at imminent risk of requiring hospitalization. Safety and efficacy of repeated treatment or prophylaxis courses have not been studied. Efficacy of TAMIFLU for treatment or prophylaxis has not been established in immunocompromised patients. Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. TAMIFLU has not been shown to prevent such complications. Hepatic Impairment The safety and pharmacokinetics in patients with hepatic impairment have not been evaluated. Renal Impairment Dose adjustment is recommended for patients with a serum creatinine clearance 30 mL min see DOSAGE AND ADMINISTRATION ; . Serious Skin Hypersensitivity Reactions Rare cases of anaphylaxis and serious skin reactions including toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme have been reported in postmarketing experience with TAMIFLU. TAMIFLU should be stopped and appropriate treatment instituted if an allergic-like reaction occurs or is suspected. Neuropsychiatric Events There have been postmarketing reports mostly from Japan ; of self-injury and delirium with the use of TAMIFLU in patients with influenza. The reports were primarily among pediatric patients. The relative contribution of the drug to these events is not known. Patients with influenza should be closely monitored for signs of abnormal behavior throughout the treatment period. Information for Patients Patients should be instructed to begin treatment with TAMIFLU as soon as possible from the first appearance of flu symptoms. Similarly, prevention should begin as soon as possible after exposure, at the recommendation of a physician. Patients should be instructed to take any missed doses as soon as they remember, except if it is near the next scheduled dose within 2 hours ; , and then continue to take TAMIFLU at the usual times. TAMIFLU is not a substitute for a flu vaccination. Patients should continue receiving an annual flu vaccination according to guidelines on immunization practices, for example, clozapine mechanism of action.
Volume 6 Issue 1 President CEO Philip W. Eatom Medical Director Adult Services Alvydas Baris, M.D Medical Director Adolescent Services Thomas Wright, M.D. Vice President of Marketing Janis Waddell Editor Graphic Designer Michelle Francis and coreg.
Cordarone amiodarone amiodarone cordarone images cordarone drug interactions user comments: be the first to write a comment about cordarone see also: arrhythmias all services a-z drug list drugs & medications diseases & conditions news & articles pill identifier interactions checker drug side effects drug image search new drug approvals new drug applications fda drug alerts clinical trial results patient care notes medical encyclopedia medical dictionary medical videos - community forums for professionals drug imprint codes medical abbreviations veterinary drugs contact us news feeds advertise here recent searches prevacid naprapac xyzal amlodipine ibuprofen gamunex symbicort actoplus met protopic hydroxyzine aromasin alli viagra propecia xenical botox levitra tricor myfortic gammagard ambien relafen kaletra clozapine baycol ativan recently approved totect acam2000 somatuline depot evithrom zingo selzentry evamist calomist privigen atralin gel more.
Table 1. Histological stage, gender, and age at diagnosis. Male Stage I II III IV Total n 0 1 14.2 42.8 Age Mean SE ; 0 63 66.38.5 65.77.2 * n 3 27 Female % 3.2 28.7 57.4 Age Mean SE ; 61.38.3 54.32.3 56.21.5 * n 3 28 Total % 3.0 27.7 56.4 Age Mean SE ; 61.38.3 54.62.2 56.71.5 and losartan.
Of randomized trials. J Psychiatry 1999; 156: 990-999. Frye MA, Ketter TA, Altshuler LL, et al. Clozapiine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91-104. Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24: 381-390. Atkin K, Kendall F, Gould D, Freeman H, Licherman J, O'Sullivan. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483-488. Rudolf J, Grond M, Neveling M, Heiss WD. Closapine induced agranulocytosis and thrombocytopenia in a patient with dopaminergic psychosis. J Neural Trans 1997; 104: 1305-1311. Eranti S, Chaturvedi SK. Marked thrombocytopenia count variations without agranulocytosis due to clozapine. Indian J Psychiatry 1998; 40: 300-302. Kumar V, Cotran RS, Robbins SL. Basic pathology. 6th ed. Philadelphia: WB Saunders Company; 1997. World Health Organization. The ICD-10 mental and behavioral disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
Clozapine drug interactions
Within 4 to 10 weeks of exposure but neither dose nor duration is a reliable predictor of this problem. Agranulocytosis associated with other antipsychotic drugs has been reported to occur with a greater frequency in women, the elderly, and in patients who are cachectic or have serious underlying medical illness; such patients may also be at particular risk with clozapine, although this has not been definitely demonstrated. WBC Count and ANC Monitoring Schedule Table 1 provides a summary of the frequency of monitoring that should occur based on various stages of therapy e.g., initiation of therapy ; or results from WBC count and ANC monitoring tests e.g., moderate leukopenia ; . The text that follows should be consulted for additional details regarding the treatment of patients under the various conditions e.g., severe leukopenia ; . Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat or any other signs of infection occurring at any time during clozapine therapy. Such patients should have a WBC count and ANC performed promptly. Table 1. Frequency of Monitoring based on Stage of Therapy or Results from WBC Count and ANC Monitoring Tests and crestor and clozapine.
Authors' conclusions Clozwpine appears to All cause, 396; external reduce mortality in including suicide ; , 122 suicide, severe schizophrenics 75 circulatory, 110 acute by reducing suicide myocardial infarction, 11; rates pulmonary embolism, 19; Comments conduction disorders or sudden death, 12 respiratory, Many subdivisions 31 pneumonia influenza, 11 of data, no other significant results neoplasms, 21; digestive, 16; mental, 13; nervous, 11 seizures, 4 infections, 6 septicemia or agranulocytosis, 3 other or unknown, 66 Intervention: mortality in patients aged 1054 years All-cause mortality, 396 versus general population, 229; SMR versus general population, 1.73 95% CI, 1.56 to 1.91 ; All-cause mortality in current cl0zapine users deaths 100, 000 person years ; , 322 versus 693 in past 106 days since most recent WBC for active clozap8ne use ; users; SMR, 0.46 95% CI, 0.37 to 0.59 ; Suicide in current cloazpine users, 39 versus 222 in past 106 days since most recent WBC for active clozapine use ; users; SMR, 0.17 95% CI, 0.10 to 0.30.
INTRODUCTION An amputation is a destructive surgery that can be considered a constructive one when it diminishes the disability and the ilness and restores functional ability and quality of life to the patient. After the amputation, the amputee begins a new, complex and, sometimes, problematic phase of his life. AIMS Caracterization of the patients followed at the Amputees Consultant of the Physical and Rehabilitation Medicine PRM ; Service of hospitais da Universidade de Coimbra hUC ; and evaluation of their professional reintegration. METhODS This clinical study was conducted at hUC's PRM Service, by collecting the data from the file of the Ampu and rosuvastatin.
This complication occurs in about 1% of people taking clozapine, most often within three months of treatment and peaking in the third month.
TIER DRUG NAME sertraline CELEXA LEXAPRO PAXIL PAXIL CR PROZAC PROZAC WEEKLY ZOLOFT 5.5.1.4 OTHER ANTIDEPRESSANTS budeprion SR 150MG bupropion HCl bupropion SR mirtazapine trazodone HCl venlafaxine CYMBALTA EFFEXOR EFFEXOR XR REMERON SOL TAB WELLBUTRIN SR WELLBUTRIN XL 5.5.2 MAO INHIBITORS EMSAM 5.6 ANTIVERTIGO AND ANTIEMETIC DRUGS prochlorperazine maleate trimethobenzamide HCl ANZEMET EMEND KYTRIL ZOFRAN IN DEXTROSE ZOFRAN ODT 5.7.1 ANTIPARKINSON ANTICHOLINERGIC DRUGS COGENTIN 5.7.2 OTHER ANTIPARKINSON DRUGS bromocriptine mesylate carbidopa levodopa selegiline HCl APOKYN AZILECT COMTAN MIRAPEX REQUIP SINEMET CR STALEVO ZELAPAR 5.8 ANTIPSYCHOTIC DRUGS clozapine haloperidol haloperidol decanoate thioridazine HCl ABILIFY, -DISCMELT QPD X X X QPD X QPD QPD QPD X X X QPD X QPD QPD QPD QPD QPD QPD X X X QPD QPD QPD QPD X X X QPD PA QPD QPD QPD QPD QPD QPD QPD QPD X X X.
Authors' conclusions Sex: 128 male Results suggest basis N: 183 for re-evaluation of Illness: schizophrenia riskbenefit assessDose: mean, or schizoaffective ment of clozapine, that 500 mg day disorder is, that overall morFor 88 patients in final analysis, bidity and mortality Duration: Diagnosis: DSM-III-R before-clozapine after-clozapine of patients with mean follow-up results in numbers of patients ; neuroleptic-resistant N: 183 3.5 years SD are as follows: no suicidal schizophrenia are 1.6 ; range 6 thoughts, 47 77; suicidal less with clozapine Duration of illness: months to 7 thoughts, plans, or threats, 9 7; treatment than with mean 14 years SD 8 ; years ; unintentional self-harm, 10 1; typical neuroleptic suicide attempts with low drugs because of less Concomitant Special probability of success, 17 3; suicidality.This concharacteristics: medications: suicide attempts with high clusion also has implipatients divided into virtually all probability of success, 5 0 cations for increasing neuroleptic-responsive patients use of clozapine with n 237 ; and received only By examining frequencies as Six further neuroleptic-responsive neuroleptic-resistant clozapine; function of time withinpatients patients n 183 ; illnesses; only benzodiazepines excluded from subjects or dependent-samples latter group treated used analysis ; and using cumulative Comments final analysis with clozapine and intermittently No direct comparison because they logits to represent suicidality followed-up in study during titration of clozapine with had received ordinally, a significant time period effect found chi-squared, other drugs or in 6 months Further details: of 35.82; df 2; p 0.0001 ; neuroleptic-responsive 88 participants included clozapine indicating that pattern of patients therapy and in final analysis, 15 suicidality changed over time further 19 had schizoaffective and change was towards were lost to disorder and all had lowering of suicidality follow-up taken clozapine for 6 months Total in final analysis, 88 Intervention: clozapine Age: 34 years SD 10 ; Intervention: 70 participants who withdrew early took clozapine for mean period of 202 days SD 205 none of these made any suicide attempts continued.
Development One of the biggest changes to occur in 2005 was when the General Intensive Care Unit GICU ; became responsible for the operational management of a Burns Intensive Care Unit BICU ; with two beds. This meant that the critical care needs of these patients would be provided by the GICU staff, while the burns unit staff would provide expert care in the management of the burns wounds. The unit has admitted and looked after 30 patients this year. While the staff viewed the merger on the whole as very positive with excellent learning opportunities a number of issues were raised. These were: Education and training Patient allocation Culture Junior nurses working on the unit Isolation Equipment Information Infection Control In order to deal with these issues constructively a small working group was established with core members from GICU and BICU. In the last year a number of small but significant changes have taken place. These are outlined in Table 1. The plan over the next year is to continue to build on the good work which has been started. Finally, it is extremely important to mention and thank all the staff on the burns and the Intensive Care Unit for their maturity, co-operation and hard work. It has been challenging at times but in the end, if the patient receives excellent care, then it has been worth it. Jane-Marie Hamill Clinical Nurse Leader, for instance, clozapine agranulocytosis.
Received April 10, 1997. Revision received May 28, 1997. Accepted June 3, 1997. Address correspondence and requests for reprints to: S.J. Hurel, Department of Medicine, Royal Victoria Infirmary, Queen Victoria Road, Farmington Place, Newcastle-Upon-Tyne, United Kingdom NE1 4LP and mebeverine.
BENEFICIAL Cpozapine compared with standard antipsychotic drugs ; One systematic review in people resistant to standard antipsychotic drugs found that clozapine improved symptoms after 12 weeks and after 2 years compared with standard antipsychotic drugs. One systematic review found no significant difference in symptoms between clozapine and other new antipsychotic drugs in people resistant to standard antipsychotic drugs. UNKNOWN EFFECTIVENESS Olanzapine Small RCTs identified by a systematic review found no significant difference in psychotic symptoms over 8 weeks between olanzapine and chlorpromazine or between olanzapine and clozapine.
If the Court finds by clear and convincing evidence that the person is mentally ill and requires specialized mental health care and psychiatric inpatient services that cannot be provided in a correctional facility, the court may order the transfer of the prisoner from the adult correctional institutions, to be detained in the facility provided for in section [1 of the Mental Health Law]. Id. 40.1-5.3-7 b ; . Once transferred, an inmate has a statutorily prescribed right to treatment, as.
S of January 1, 2004, if your child is enrolled as a student dependent on your HMO plan and lives outside our Pennsylvania service area while attending school, your child may be covered for the following services provided by nonparticipating providers when he or she is sick or injured: Allergy. Allergy antigen serum. Corrective appliances. * Diabetic supplies services. Dialysis. * Laboratory tests. Physician services for illness and injury. Radiology and nuclear medicine. * Rehabilitation services outpatient only ; . * * Prior authorization required for these services. If you are not sure if a service requires prior authorization, please contact us before you receive the service. Refer to your group contract and subscription agreement for details of covered services, or call us with questions.
Reduces your risk of dying from a disease. Failure to undergo such tests may represent a missed opportunity to pick up an early cancer and reduce the progression of disease and ultimately death. I would recommend that you go with your sister if you live near each other ; to a genetic counselor, possibly to the one she used, since your history will already be familiar to the genetic counselor. If you do have a genetic mutation in the BRCA 1 or 2 gene, chances are your physician will want to step up breast surveillance. He or she may recommend a mammogram, or possibly a sonogram, which I like as an extension of a physical examination particularly in dense breasts. And there has been some exciting news on MRI magnetic resonance imaging ; . There is no exposure to radiation with MRI. A study published in the New England Journal of Medicine reported on 1, 900 eligible women who were considered to be at high risk of developing breast cancer, either due to family history or having inherited a genetic mutation. In this group 359 women were found to carry a gene mutation!
Drug Name FAZACLO TAB 25MG Clozapine ; FELBATOL SUS 600 5ML Felbamate ; FELBATOL TAB 400MG Felbamate ; FELBATOL TAB 600MG Felbamate ; fentanyl td patch 72hr 100 mcg hr fentanyl td patch 72hr 25 mcg hr fentanyl td patch 72hr 50 mcg hr fentanyl td patch 72hr 75 mcg hr fluoxetine hcl cap 10 mg fluoxetine hcl cap 20 mg fluoxetine hcl cap 40 mg fluoxetine hcl solution 20 mg 5ml fluoxetine hcl tab 10 mg fluoxetine hcl tab 20 mg fluphenazine decanoate inj 25 mg ml fluphenazine hcl elixir 2.5 mg 5ml fluphenazine hcl inj 2.5 mg ml fluphenazine hcl oral conc 5 mg ml fluphenazine hcl tab 1 mg fluphenazine hcl tab 10 mg fluphenazine hcl tab 2.5 mg fluphenazine hcl tab 5 mg flurbiprofen tab 100 mg flurbiprofen tab 50 mg fluvoxamine maleate tab 100 mg fluvoxamine maleate tab 25 mg fluvoxamine maleate tab 50 mg gabapentin cap 100 mg gabapentin cap 300 mg gabapentin cap 400 mg gabapentin tab 100 mg gabapentin tab 300 mg gabapentin tab 400 mg gabapentin tab 600 mg gabapentin tab 800 mg GABARONE TAB 100MG Gabapentin ; GABARONE TAB 300MG Gabapentin ; GABARONE TAB 400MG Gabapentin ; GABITRIL TAB 12MG Tiagabine HCl ; GABITRIL TAB 16MG Tiagabine HCl ; GABITRIL TAB 2MG Tiagabine HCl ; GABITRIL TAB 4MG Tiagabine HCl ; GEODON CAP 20MG Ziprasidone HCl ; GEODON CAP 40MG Ziprasidone HCl ; GEODON CAP 60MG Ziprasidone HCl ; GEODON CAP 80MG Ziprasidone HCl ; GEODON INJ 20MG Ziprasidone Mesylate ; haloperidol lactate inj 5 mg ml haloperidol lactate oral conc 2 mg ml haloperidol tab 0.5 mg.
Means of severity show the most changes in these regions, particularly in the clozapine group.
Clozapine information
6.1 Global state 6.1.1 Not responded Only one study Riera 2004 ; provided data for the comparison of aripiprazole and standard care. Response rate, dichotomised to those who were considered not to have responded, did significantly favour aripiprazole NNT 5 CI 4 54% versus 78% not responded for the standard care group ; . This result, although encouraging does leave unanswered questions on the accuracy of the result because the standard care group were given either typical or atypical antipsychotics zisprasidone, olanzapine, risperidone, quetiapine, clozapine at varying doses ; and the study was open label. 6.2 Satisfaction with treatment - Not satisfied with care Riera 2004, also reported on satisfaction which we dichotomised to not satisfied with care. Results were significantly in favour of aripiprazole compared with the standard care group NNT 4 CI 4 However, again some doubt remains as this was open label with the control group receiving different medication and perhaps if the control group had all received the same drug the size affect may have been different. 6.3 Leaving the study early - due to any reason Attrition rates from the Riera 2004 study did significantly favour aripiprazole with 35% leaving early compared with 43% in the standard care group NNT 13 CI 8 39. Here again doubts remain given the lack of blinding and mixed comparator group which is a pity given these positive results for aripiprazole compared with standard care, especially as this study was by far the largest, randomising an impressive 1599 participants.
Protection and loss-spreading that underlie the compensation model also lie at the heart of the various no-fault schemes that were proposed over the last fifty years. 5.2 A short history of no-fault Beginning in the 1950s the idea of abolishing the tort system altogether in favour of private or social first-party insurance gained support, particularly with regard to motor accidents. With the exception of New Zealand no country has implemented a comprehensive scheme of first-party insurance for personal injury, 74 but many North-American jurisdictions have adopted more modest versions of it which at least provide basic protection of the traffic victim on a no-fault basis. No-fault schemes rest on the same assumptions as the compensation model discussed above. The combination of tort law and liability insurance is discredited for its inability to funnel compensation to every victim who needs it. In the area of medical liability for example, liability is contingent on malpractice, and only those victims who succeed in proving malpractice are allowed to collect. Patient insurance schemes try to go further in dispensing with the fault requirement and instead merely demand proof of iatrogenic injury.75 On the other hand, the concern with deterrence is played down. In reality, it is said, people do not think about liability issues before they act. If doctors, for instance, are deterred from careless behaviour, it is out of concern for their reputation, both among their peers and among potential clients, and not because of the threat of being held liable for the damage caused. These assumptions underlie the Swedish scheme of first-party.
© 2005-2007 Generic.fizwig.com, Inc. All rights reserved.
|
|
